obesity drug maritide news - Search News

Amgen, Obesity

The New York Times on MSN · 4d

New Obesity Drug MariTide Helps Patients Lose Up to 20% of Weight, Early Data Shows

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 percent of their weight in a year. The drug, MariTide, is given by injection once a month,

CNBC on MSN · 4d

Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau

The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other experimental treatments.

BioPharma Dive · 4d

Amgen obesity drug cuts weight in study, but results miss Wall Street’s high mark

Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential rival to Wegovy and Zepbound.

16hon MSN

Eli Lilly and Novo Nordisk’s Obesity Moat Just Got Stronger

Data from their most serious competitor, Amgen, suggests the biotech won’t upstage the market leaders.

4d

What's Next for Amgen Obesity Drug After Investors Disappointed by Results

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

Amgen's big reveal of obesity data falls a bit flat

William Blair's assessment is that MariTide is an improvement on current obesity therapies with a profile that "will be ...

FierceBiotech4d

Amgen's monthly obesity drug matches competition in phase 2, but investors are unimpressed

MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...

Pharmalittle: We’re reading about Medicare obesity drug coverage, a first-of-its-kind 340B analysis, and more

The Biden administration is proposing a major expansion of how Medicare and Medicaid cover Wegovy and Zepbound ...

Investor's Business Daily on MSN4d

Amgen Dives 5% Despite 'Truly Remarkable' Results For Obesity Treatment

Amgen stock tumbled Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results